Navigation Links
Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
Date:9/23/2011

tellation of collaborative relationships with large and small companies advancing antisense drugs and the antisense technology platform," said B. Lynne Parshall, COO and CFO of Isis.  "A necessary component of our strategy is that we vigorously pursue infringement of our intellectual property.  The exemption from patent infringement for drug development was created to encourage rapid introduction of generic medicines.  We allege Santaris' activities are not protected by this exemption and that case law affirms our position."  

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 24 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' intellectual property position and its value in drug discovery and development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the end
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SHANGHAI, March 5, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the pharmaceutical, ... and the United States, today announced its financial results ... Fourth-Quarter 2014 Highlights , Net Revenues ... , Laboratory Services Net Revenues Grew 17.7% Year Over ...
(Date:3/5/2015)... Germany , March 5, 2015 ... and CureVac today announced that the foundation has ... million) in CureVac, a leading clinical-stage biopharmaceutical company ... the agreement, the foundation will also provide separate ... based on CureVac,s proprietary messenger RNA (mRNA) platform. ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
(Date:3/6/2015)... 06, 2015 At Natural Products ... today the launch of its powerful, location-aware iOS ... and sustainable products at any retailer that carries ... at Expo West Booth 6054. , Makeena’s ... Kosher, non-GMO, organic, Paleo, and vegan, among many ...
(Date:3/6/2015)... Since Medicare began paying for chronic care ... an overwhelming demand from providers for straightforward guidance on ... The Centers for Medicare & Medicaid Services (CMS) ... updated white paper—“ Providing and Billing Medicare for Chronic ... yet practical “how to” manual for providers looking to ...
(Date:3/6/2015)... 06, 2015 Jvion, the Atlanta-based ... of a Clostridium Difficile (C Diff) predictive use ... Diff use case is the latest in a ... acquired infections, chronic conditions, and individual illnesses. Using ... Diff solution flags at risk individuals to help ...
(Date:3/6/2015)... Utilizing the latest in nutritional science to help ... has enabled Diet Doc to add powerful new ... of fat loss enhancement medications. And now, they are ... to help people throughout the country begin losing dangerous ... appealing to new clients because they can receive Appetite ...
(Date:3/6/2015)... March 06, 2015 The Gluten-Free ... Celiac Association, is pleased to announce that Dufflet ... Rosenberg, has expanded their product line of gluten-free ... as scrumptious and as satisfying as any of ... scratch, and never contains hydrogenated fats or oils, ...
Breaking Medicine News(10 mins):Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
... RESEDA, Calif., June 16 The famed nonprofit Los ... prevention and,fitness program designed to address one of the ... by the Jewish Community Foundation,the largest manager of charitable ... new fall prevention and fitness program becomes part of ...
... RELEASE, 16 June 2008] A unique new study from the ... of families and the public have little impact on if ... or the opposite sex. Instead, hereditary factors and the individual,s ... sexual partners. , The study is the largest in the ...
... recognize partners, innovative use of Microsoft technology to ... customer expectations and solve business ... partners,that delivered exemplary solutions to customers, Microsoft Corp. ... Microsoft Partner of the,Year Awards. The awards honor ...
... 16 BME (BioMedical Enterprises,Inc.), a privately held ... implant technology, today announced the launch of the ... fixation of,bone., The BOSS is an orthopaedic ... adhesion. Like the BME OSStaple(TM) product line, the ...
... Comprehensive Cancer Center, has been appointed by President Bush to the ... appointees named to the board on June 12, 2008. , The ... National Cancer Institute (NCI). The role of the board is ... Services and the director of the NCI on issues that ...
... provider based at The University of Queensland, and Q-Pharm, ... have formed a strategic alliance. , The alliance ... clients in the biotechnology and pharmaceutical industries. , ... the two businesses, which are both commercialisation enterprises of ...
Cached Medicine News:Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 2Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 2Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 4Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 5Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 6Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 7Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2Health News:TetraQ and Q-Pharm form strategic alliance 2Health News:TetraQ and Q-Pharm form strategic alliance 3
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Identity pacemaker family, which ... pacemaker, provides clinicians with the ... including the revolutionary AF Suppression™ ... U.S. commercially approved algorithm designed ...
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks....
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
Medicine Products: